BCYC News and Press, Bicycle Therapeutics plc From 05/07/20

- Significant recent progress achieved across pipeline of innovative Bicycle ® - based therapies for oncology and beyond - Dosing underway in Phase I dose escalation of BT5528 in combination with nivolumab - Continued to strengthen corporate leadership with appointment of Ge...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycles ®) technology, today announced that management will present at the Bank of America 2020 Health Care Conference...

- Monotherapy Phase I dose escalation remains ongoing; BT5528 appears well-tolerated as dosing approaches clinically relevant levels - BT5528 is the Company’s first second-generation Bicycle® Toxin Conjugate and targets EphA2, a target for which antibody-based approaches...

The biotechnology industry's chock-full of stocks that could quickly skyrocket overnight and make you filthy rich in the process. All three of these clinical-stage biotechs are relatively small at the moment, but they have potential blockbuster drugs in development that could send their stock pr...

Axovant Gene Therapies (NASDAQ: AXGT ) initiated with Overweight rating and $11 (209% upside) price target at Cantor Fitzgerald. More news on: Axovant Gene Therapies Ltd., Biohaven Pharmaceutical Holding Company Ltd., Coherus BioSciences, Inc., Healthcare stocks news, Stocks on the move, ,...

- Phase I dose escalation completed for BT1718 — RP2D established and preliminary signs of anti-tumor activity observed, including one partial response - Dosing complete in second cohort of Phase I dose escalation for BT5528 — all doses administered in Phase I to date app...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycles ®) technology, today announced that management will participate in a panel discussion on bispecifics at the Ca...

The coronavirus pandemic has been bad news for nearly every type of asset class in 2020. On the flip side, this indiscriminate wave of selling has undoubtedly created some amazing buying opportunities for long-term investors. Biotech stocks, for instance, were particularly hard hit by the market...

Bicycle Therapeutics (NASDAQ: BCYC ): Q4 GAAP EPS of -$0.25 beats by $0.26 . Revenue of $5.28M (+398.1% Y/Y) beats by $4.56M . Press Release More news on: Bicycle Therapeutics plc, Earnings news and commentary, Healthcare stocks news,

- BT1718 on track for Phase IIa initiation in 2020; BT5528 Phase I dose escalation is ongoing; BT8009 on track for Phase I trial initiation in 2020 - IND-enabling activities for lead TICA™ BT7480 continue to progress - Cash was $92.1 million at December 31, 2019, which excl...